Ricevi le ultime notizie sulle azioni Aditxt con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di ADTX

Ultime notizie per

Aditxt

Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.

Aditxt Inc

Small Cap

Press Releases

Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference

Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative

Earnings

Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law

Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030

Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

Social Media

General

Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

Evofem Announces Voting Results from Special Meeting of Stockholders

Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market

ADTX

EVFM

Apollomics

Azitra

Bone Biologics

BriaCell Therapeutics

Bio Green Med Solution, Inc. - 6% Convertible Preferred Stock

Bio Green Med Solution

BioVie

Celularity

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

ETHZilla

GT Biopharma

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Liminatus Pharma

Lixte Biotechnology Holdings, Inc. - Warrants

Lixte Biotechnology

Medicus Pharma

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Protagenic Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Revolution Medicines

Sunshine Biopharma

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Silexion Therapeutics

HC Wainwright & Co.

Comments

Aditxt Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO